Product image of Neisvac-C (N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid A) supplied by GNH India

Neisvac-C

Active Ingredient:
N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid A
Origin:
EU

Neisvac-C (N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid A)

Neisseria meningitidis Group C (Strain C11) polysaccharide (de-O-acetylated) conjugated to tetanus toxoid A, the active ingredient in Neisvac-C, is a vaccine presented as an injectable solution for intramuscular use. It induces active immunity to prevent invasive disease caused by Neisseria meningitidis serogroup C in at‑risk populations.

GNH India supplies Neisvac-C as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Pfizer S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Neisvac-C is a conjugate vaccine that targets meningococcal serogroup C infection. It is indicated for:

  • Invasive meningococcal disease caused by Neisseria meningitidis serogroup C: provides active immunity to prevent infection.
  • Outbreak control of serogroup C meningococcal disease: helps reduce transmission during epidemic situations.
  • Travel to regions with high serogroup C prevalence: offers protection for travelers at risk of exposure.

How It Works

  • Neisvac-C contains a de‑O‑acetylated polysaccharide from Neisseria meningitidis group C covalently linked to tetanus toxoid. The conjugate is taken up by antigen‑presenting cells, processed, and presented to T‑cells, which stimulate B‑cell production of high‑affinity anti‑polysaccharide antibodies, establishing long‑lasting protective immunity against serogroup C meningococcus.

Side Effects

Neisvac-C may cause a range of post‑vaccination reactions. Monitoring and reporting are essential.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling: localized erythema or edema.
  • Fever: transient low‑grade temperature rise.
  • Headache: mild headache within 24 hours.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare demyelinating neuropathy.
  • Seizures: uncommon neurologic event.
  • Severe hypotension: marked drop in blood pressure after injection.
  • Acute allergic reaction: urticaria, angioedema, or bronchospasm.

Precautions & Warnings

Before administering Neisvac-C, consider the following safety measures.

  • Pregnancy: safety not established; use only if benefit outweighs risk.
  • Breastfeeding: limited data; consult healthcare professional.
  • Immunocompromised patients: vaccine may elicit a reduced immune response.
  • Prior allergic reaction to tetanus toxoid or any component: avoid vaccination.
  • Acute febrile illness: defer vaccination until recovery.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Neisvac-C has limited known drug interactions, but caution is advised.

Major Interactions (Avoid)

  • Immunoglobulin therapy: may diminish vaccine‑induced antibody response.
  • Live bacterial vaccines administered concurrently: could interfere with immune response.

Moderate Interactions (Monitor Closely)

  • Antipyretics (e.g., acetaminophen, ibuprofen): may mask fever post‑vaccination.
  • Other injectable vaccines given on the same day: consider separate anatomical sites.
  • Corticosteroids or immunosuppressants: may reduce immunogenicity of the vaccine.

Frequently Asked Questions

Neisvac-C is a conjugate vaccine indicated to prevent invasive disease caused by Neisseria meningitidis serogroup C. It is used in individuals at risk of meningococcal infection, including travelers to endemic areas and during outbreak control.

The vaccine contains a de‑O‑acetylated polysaccharide from serogroup C linked to tetanus toxoid. This conjugate stimulates T‑cell help, leading to robust B‑cell production of anti‑polysaccharide antibodies that provide long‑lasting protection against the bacteria.

The dosing regimen for Neisvac-C is determined by the prescribing healthcare professional based on the patient’s age, health status, and local immunization guidelines. The prescriber will specify the number of doses and interval.

Safety data for Neisvac-C in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and after consultation with a qualified healthcare provider.

To order Neisvac-C, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Neisvac-C is a conjugate vaccine targeting serogroup C, whereas some alternatives are polysaccharide‑only or cover multiple serogroups (A, C, W, Y, B). Conjugate vaccines like Neisvac-C generally induce stronger, longer‑lasting immunity and are effective in younger children.

Neisvac-C must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Do not use the product if it has been exposed to temperatures outside this range.

Neisvac-C is given as a single intramuscular injection, typically into the deltoid muscle of the upper arm. The injection is performed by a qualified healthcare professional using aseptic technique.

Serious adverse events, although rare, include anaphylaxis, Guillain‑Barré syndrome, severe allergic reactions, seizures, and profound hypotension. Any signs of a severe reaction require immediate medical attention.

Individuals with a known severe allergy to tetanus toxoid or any component of the vaccine should not receive Neisvac-C. It is also contraindicated in persons who have experienced a severe immediate hypersensitivity reaction after a previous dose.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid A

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT